Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials |
2019-12-02 |
Formo Bio–SEVERAL: investment, 201912 seed financing round co-led by Agronomics + M Ventures |
2019-12-01 |
MLM Medical Labs–Great Point Partners: investment, 201912 acquisition MLM becomes portfolio company of GPP |
2019-12-01 |
Novartis–Oxford BioMedica: lentiviral vector technology, 201912– supply agreem extension for 5y |
2019-12-01 |
ECBF–EU (govt): investment, 201911–202010 first closing totalling €82m incl cornerstone investor EIB that has committed up to €100m |
2019-11-29 |
ECBF–SEVERAL: investment, 201911–202010 first closing €82m from cornerstone investor EIB + 3 private investors + target size of €250m |
2019-11-29 |
ViGeneron–MC Services: public relations, 201911 service existent media + investor relations by MC Services |
2019-11-28 |
ViGeneron–Sequoia Capital: investment, 201911 financing round Series A incl co-lead investor Sequoia Capital China |
2019-11-28 |
ViGeneron–SEVERAL: investment, 201911 financing round Series A co-led by WuXi AppTec + Sequoia Capital China |
2019-11-28 |
ViGeneron–WuXi PharmaTech: investment, 201911 financing round Series A incl co-lead investor WuXi AppTec |
2019-11-28 |
MaxiVax–EU (govt): grant, 201911 Horizon 2020 EIC Accelerator grant €2.785m |
2019-11-26 |
MaxiVax–SEVERAL: investment, 201911 financing round Series B2 CHF5m from existing + new investors |
2019-11-26 |
Single Use Support–SHS Capital: investment, 201911 investment by SHS Gesellschaft für Beteiligungsmanagement within framework of capital increase |
2019-11-26 |
Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec |
2019-11-25 |
Medicines Company–Novartis: investment, 201911–202001 cash tender offer $9.7b at $85/share |
2019-11-24 |
Immunitas Therapeutics–Bayer: investment, 201911 financing round Series A totalling $39m incl co-lead investor Leaps by Bayer |
2019-11-21 |
Immunitas Therapeutics–Evotec: investment, 201911 financing round Series A totalling $39m incl co-investor Evotec |
2019-11-21 |
Immunitas Therapeutics–Merck (DE): investment, 201911 financing round Series A totalling $39m incl co-investor M Ventures |
2019-11-21 |
Immunitas Therapeutics–Novartis: investment, 201911 financing round Series A totalling $39m incl co-lead investor Novartis Venture Fund |
2019-11-21 |
Immunitas Therapeutics–SEVERAL: investment, 201911 financing round Series A $39m co-led by Leaps by Bayer + Novartis Venture Fund |
2019-11-21 |
LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights |
2019-11-20 |
Causaly–SEVERAL: investment, 201911 financing round Series A $5m led by Pentech Ventures + incl EBRD VC + Marathon VC et al. |
2019-11-19 |
CRISPR Therapeutics–SEVERAL: investment, 201911–201912 public offering $315.25m with 4.25m+637.5k common shares at $64.5/share |
2019-11-19 |
Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share |
2019-11-19 |
Novartis–Causaly: Natural Language Processing s/w, 201911 collab existent |
2019-11-19 |
Rodin Therapeutics–Alkermes: investment, 201911 acquisition $100m upfront cash + $850m milestones by Alkermes |
2019-11-18 |
Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH |
2019-11-13 |
Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures |
2019-11-13 |
Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures |
2019-11-13 |
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson |
2019-11-13 |
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati |
2019-11-13 |
Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. |
2019-11-13 |
Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec |
2019-11-12 |
Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform |
2019-11-12 |
NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines |
2019-11-12 |
Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem |
2019-11-12 |
Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED |
2019-11-11 |
eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer |
2019-11-07 |
eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures |
2019-11-07 |
eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners |
2019-11-07 |
Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform |
2019-11-07 |
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA |
2019-11-06 |
Vifor Pharma–Evotec: drug RnD, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
A2 Biotherapeutics–Nextech: investment, 201911 emerges from stealh with financing round Series A totalling $57m incl investor Nextech Invest |
2019-11-05 |
A2 Biotherapeutics–SEVERAL: investment, 201911 emerges from stealh with financing round Series A $57m |
2019-11-05 |
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners |
2019-11-04 |
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners |
2019-11-04 |
Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH |
2019-11-04 |
Celonis–SEVERAL: investment, 201806 financing round Series B $50m |
2019-11-01 |
Celonis–SEVERAL: investment, 201911 financing round Series C $290m |
2019-11-01 |
TolerogenixX–SEVERAL: investment, 201911 financing round Series A 1st closing €4.1m with business angels |
2019-11-01 |
Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance |
2019-10-31 |
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma |
2019-10-31 |
AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm |
2019-10-30 |
Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
NikYang Enterprises–Labforward: electonic lab notebook, 201910 collab existent NikYank Enterprises Ltd is Chinese partner of Labforward GmbH |
2019-10-24 |
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion |
2019-10-22 |
MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG |
2019-10-22 |
MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m |
2019-10-22 |
Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments |
2019-10-21 |
Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments |
2019-10-21 |
Danaher–Sartorius: investment, 201910–2020 acquisition $750m 3 life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal |
2019-10-21 |
Avacta–SEVERAL: investment, 201910– proposed placing + subscription up to £9m with 59.8m nrew ordinary shares at 15p/share |
2019-10-18 |
Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures |
2019-10-17 |
Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group |
2019-10-17 |
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m |
2019-10-17 |
Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners |
2019-10-16 |
Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital |
2019-10-16 |
Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners |
2019-10-16 |
Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner |
2019-10-16 |
Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico |
2019-10-16 |
Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF |
2019-10-15 |
Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF |
2019-10-15 |
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK |
2019-10-15 |
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr |
2019-10-15 |
Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr |
2019-10-15 |
Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-15 |
CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP |
2019-10-15 |
Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics |
2019-10-10 |
FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck |
2019-10-10 |
Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data |
2019-10-09 |
Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation |
2019-10-08 |
GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies |
2019-10-08 |
Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-08 |
4SC–SEVERAL: investment, 201910–201911 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights |
2019-10-07 |
4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS |
2019-10-07 |
Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity |
2019-10-07 |
Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |